SILVER SPRING, Md. -- Another line of products from a major tobacco manufacturer—in this case, R.J. Reynolds Tobacco Co. and six of its snus products—is about to go before a U.S. Food and Drug Administration (FDA) review committee, which will help determine what claims the company can make in terms of the products being reduced or “modified” risk to consumers, the agency announced.
The FDA issued what it calls a Federal Register notice announcing that its Tobacco Products Scientific Advisory Committee (TPSAC) will review six of Reynolds’ snus products from Sept. 13-14 at the FDA’s White Oak campus in Silver Spring, Md.
The committee will discuss scientific issues related to the company’s modified-risk tobacco product (MRTP) applications for the Camel Snus smokeless tobacco products, which are currently under scientific review by the FDA. These products include:
- Camel Snus Frost
- Camel Snus Frost Large
- Camel Snus Mellow
- Camel Snus Mint
- Camel Snus Robust
- Camel Snus Winterchill
On Dec. 18, 2017, the FDA filed for substantive, scientific review of six MRTP applications from Winston-Salem, N.C.-based Reynolds for those products. In issuing its notice, the FDA also outlined the role of TPSAC in a Q&A format. Here's a look at that breakdown ...